TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11602855
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin (U.W.) solution
Study: 24394747
Drug: Buprenorphine Transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine Transdermal Delivery System (BTDS)
Study: 16325366
Drug: Dexrazoxane supplementation
Normalized name: Dexrazoxane
DrugBank: Dexrazoxane (DB00380)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dexrazoxane supplementation (400 mg/m²) after epirubicin infusion
Study: 16325366
Drug: Epirubicin-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin-based chemotherapy without dexrazoxane
Study: 11990278
Drug: Remifentanil 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.5 microg kg(‐1) over 30 s, followed by an infusion of 0.1 microg kg min(‐1) (group R)
Study: 11990278
Drug: Alfentanil 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 10 microg kg(‐1) over 30 s, followed by an infusion of saline (group A)
Study: 10710173
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (0.325 mg/kg)
Study: 10710173
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (0.650 mg/kg)
Study: 10710173
Drug: Intravenous cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cocaine (0.325 mg/kg) and (0.650 mg/kg)
Study: 7815715
Drug: Rectal indomethacin
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal indomethacin 50 mg plus epidural 0.1 mg buprenorphine in 8 ml of 0.25% bupivacaine and 15 micrograms buprenorphine in 1 ml of 0.25% bupivacaine at 1 ml.h‐1 for 48 h
Study: 7815715
Drug: Epidural 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural 0.1 mg buprenorphine in 8 ml of 0.25% bupivacaine and 15 micrograms buprenorphine in 1 ml of 0.25% bupivacaine at 1 ml.h‐1 for 48 h
Study: 22164930
Drug: Guided group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided group medical art therapy (MAT) for 6 weeks, facilitated by a MAT therapist.
Study: 19809344
Drug: EP-2104R (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP-2104R (4 mumol/kg intravenous bolus injection)
Study: 16969009
Drug: Single 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 0.5 mg ACTH-depot doses for the entire duration of pregnancy
Study: 16969009
Drug: Series of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Series of three 0.5 mg ACTH-depot injections every other day in the first and/or second trimester
Study: 9250558
Drug: Bromfenac 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 50 mg (3 times/day for 3 days)
Study: 8220804
Drug: Cetirizine 5
Normalized name: cetirizine 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 5 mg once daily for two weeks
Study: 3470961
Drug: PGE1 treatment
Normalized name: PGE1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE1 treatment group (0.2 ng/kg body weight/min and 15,000 I.U. heparin/d for 10 days)
Study: 3470961
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 x 500 mg aspirin and 15,000 I.U. heparin/d)
Study: 30273586
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of extended‐release liposomal bupivacaine (Exparel)
Study: 30273586
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of placebo (saline)
Study: 22967782
Drug: Naltrexone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone maintenance dose
Study: 15907239
Drug: Oral Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Misoprostol (50 microg, 4 hourly to a maximum of four doses)
Study: 15907239
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal pessary (at 6 hourly intervals up to two doses)
Study: 12769340
Drug: iCNOP (mitoxantrone
Approvals — FDA: no, EMA: no, PMDA: no
Description: iCNOP (mitoxantrone 20 mg/m2, i.v., d.1)
Study: 7485077
Drug: Loperamide 4
Normalized name: loperamide 0.4 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide 4 mg po q6h
Study: 7485077
Drug: Octreotide at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide at higher dosage levels (dose escalated to maximum of 2,400 micrograms)
Study: 19432126
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of active vitamin D3 and alendronate
Study: 19432126
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of risedronate and vitamin K2
Study: 15488108
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy (CBT)
Study: 15488108
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy (CBT)
Study: 11159242
Drug: Levobupivacaine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine and fentanyl 2 microg/mL
Study: 11159242
Drug: Levobupivacaine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine and fentanyl 3 microg/mL
Study: 9779700
Drug: Dexamethasone, high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, high‐dose cytarabine, and cisplatin (DHAP)
Study: 3207529
Drug: 4% amethocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% amethocaine formulation
Study: 3207529
Drug: Higher concentrations
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher concentrations of amethocaine (12%) in formulation C
Study: 3207529
Drug: Formulations A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulations A and B (hydrophilic)
Study: 3207529
Drug: Formulation C
Normalized name: Army Liposome Formulation component monophosphoryl lipid A
DrugBank: Monophosphoryl lipid A (DB19290)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation C (oil-in-water cream)
Study: 2119530
Drug: Metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (200 mg/day during 1 week)
Study: 2119530
Drug: Adrenaline infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusions (0.1 and 0.4 nmol kg‐1 min‐1)
Study: 786348
Drug: Adrenaline 5
Normalized name: Adrenaline 5 mg/mL eye solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline 5 mug/ml added to 1% etidocaine hydrochloride
Study: 31956998
Drug: Intensified regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified regimen with rifampin 15 mg/kg and levofloxacin for the first 60 days
Study: 31956998
Drug: Rifampin 15
Normalized name: rifampin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 15 mg/kg
Study: 31754048
Drug: Propranolol (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80-160 mg daily for 7 days)
Study: 28385346
Drug: Early administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early administration of SAP (1.5 g of cefuroxime, intravenous infusion over 2-5 min)
Study: 28385346
Drug: Late administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late administration of SAP (1.5 g of cefuroxime, intravenous infusion over 2-5 min)
Study: 17286624
Drug: Oxcarbazepine (initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (initiated at 300 mg/day, titrated to a maximum of 900 mg b.i.d.)
Study: 11309009
Drug: ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 7.5 mg. ml‐1
Study: 11309009
Drug: ropivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ropivacaine 7.5 mg. ml‐1 + 1 microg. ml‐1 fentanyl
Study: 3297574
Drug: 4-aminosalicylic acid
Normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-aminosalicylic acid (4-ASA) enemas, 1 g bid
Study: 3297574
Drug: 4-aminosalicylic acid
Normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-aminosalicylic acid (4-ASA) enemas, 2 g bid
Study: 31411975
Drug: PSA >40ng/ml,
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSA >40ng/ml, GGG5, and GGG4
Study: 29550184
Drug: Pre-treatment computed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment computed tomography (CT) findings
Study: 28089187
Drug: Multimodal cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cocktail injection with morphine (10 mg)
Study: 28089187
Drug: Multimodal cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal cocktail injection without morphine
Study: 26018036
Drug: Nasal mupirocin
Normalized name: mupirocin Nasal Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal mupirocin (Bactroban) twice daily and hexachlorophene (pHIsoHex) soaps daily for 7 days
Study: 23812521
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection (PRPplus group)
Study: 9890611
Drug: Preterm newborns
Normalized name: Vital E- Newborn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preterm newborns (mean 4.6+/‐6.9 ng/mL)
Study: 9890611
Drug: Term newborns
Normalized name: Vital E- Newborn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Term newborns (mean 19.6+/‐14.3 ng/mL)
Study: 9890611
Drug: Newborns at
Normalized name: Vital E- Newborn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newborns at approximately 6 days of life (mean 1.9+/‐1.1 ng/mL)
Study: 8915402
Drug: Taurine powder
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurine powder (6 g/day)
Study: 1853148
Drug: Cimetidine, 400
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 400 mg twice a day
Study: 1905501
Drug: Sucralfate, 1
Normalized name: Sucralfate, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate, 1 g four times a day
Study: 6421002
Drug: Gallopamil (D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (D 600) 50 mg
Study: 6421002
Drug: Gallopamil (D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (D 600) 150 mg
Study: 27352907
Drug: Patch tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch tests including baseline series plus selected allergens
Study: 20537406
Drug: Motivation enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivation enhancement therapy (MET)
Study: 18467543
Drug: CHO +
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO + Caff (8 mg/kg BM)
Study: 18467543
Drug: CHO (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO (4 g/kg body mass)
Study: 15305841
Drug: Intracerebral microdialysis
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracerebral microdialysis and bedside biochemical analyses for monitoring cerebral energy metabolism.
Study: 7598280
Drug: Milrinone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (loading dose of 50-75 micrograms/kg followed by 0.5-0.75 micrograms.kg-1.min-1 for 12-24 h)
Study: 368975
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of vitamin B6 (pyridoxine)
Study: 31065844
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake ≥ 1.1 g/kg BW
Study: 31065844
Drug: Protein intake
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein intake < 1.1 g/kg BW
Study: 30933748
Drug: Individually delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually delivered treatment
Study: 30933748
Drug: Trauma-focused treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused treatments
Study: 29237915
Drug: Auricular points
Normalized name: brilliant green
DrugBank: Brilliant green cation (DB11279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auricular points treatment combined with acupoints application therapy
Study: 22871333
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 800 mg once-daily, individualized within 400-1200 mg range
Study: 19701676
Drug: Rasburicase 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rasburicase 0.15 mg/kg/day
Study: 11201510
Drug: Isoflavone-rich soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-rich soy protein (80.4 mg/day)
Study: 11201510
Drug: Isoflavone-poor soy
Normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone-poor soy protein (4.4 mg/day)
Study: 396111
Drug: Alprenolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol (200 mg twice daily for 8 weeks)
Study: 25591723
Drug: Antiarrhythmic medication
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic medication (group II, 46 pts)
Study: 19925617
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg and 1.8 mg once-daily) plus OADs
Study: 19925617
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg and 1.8 mg once-daily) plus metformin or metformin plus rosiglitazone
Study: 19925617
Drug: Liraglutide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.2 mg and 1.8 mg once-daily) plus glimepiride
Study: 19085384
Drug: Copaxone (glatiramer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copaxone (glatiramer acetate) 20 mg weekly subcutaneous injections for 12 weeks
Study: 16816306
Drug: Nurse problem-solving
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse problem-solving treatment
Study: 14710057
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution placebo with epinephrine
Study: 2035325
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg peroral vitamin K
Study: 2035325
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg intramuscular vitamin K
Study: 7016626
Drug: Trimethoprim 200
Normalized name: trimethoprim 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 200 mg x 2 for 10 days
Study: 7016626
Drug: Nitrofurantoin 50
Normalized name: nitrofurantoin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin 50 mg x 4 for 10 days
Study: 28701602
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 mcg/kg) over 10 min before propofol (1 mg/kg)
Study: 28701602
Drug: Propofol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1 mg/kg) only
Study: 24876244
Drug: Intravenous tissue-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue-type plasminogen activator
Study: 19725966
Drug: Artesunate-mefloquine combination
Normalized name: artesunate and mefloquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-mefloquine combination therapy
Study: 15093200
Drug: Concomitant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemotherapy and radiation therapy
Study: 15093200
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment with chemotherapy first followed by radiation
Study: 2901270
Drug: Vecuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.3 mg kg‐1
Study: 29474602
Drug: Haemodialysis patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodialysis patients with BTP concentration >7.96 mg/L
Study: 29474602
Drug: Coronary angiography
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coronary angiography patients with BTP concentration >0.67 mg/L
Study: 25563312
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (GCV) 1000 mg 3 times per day for 8 weeks, plus topical 0.15% GCV ophthalmic gel and 0.1% fluorometholone eye drops.
Study: 25563312
Drug: Topical acyclovir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acyclovir (ACV) with the same ophthalmic gel and eye drops, plus oral ACV 400 mg 5 times a day for 10 weeks, then 400 mg 2 times per day for 6 months.
Study: 25563312
Drug: Negative control
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Negative control (placebo) group with topical 0.15% GCV ophthalmic gel and 0.1% fluorometholone eye drops.
Study: 17142146
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg daily with placebo colesevelam HCl twice daily (E)
Study: 17142146
Drug: ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe 10 mg daily with 1.875 g colesevelam HCl twice daily (E + C)
Study: 10873879
Drug: 8-L exchanges
Normalized name: 8-L-lysinevasopressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-L exchanges
Study: 10873879
Drug: 6-L exchanges
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-L exchanges
Study: 10873879
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (3 daily 2-L exchanges)
Study: 9110103
Drug: identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: identical placebo capsules
Study: 8249364
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human erythropoietin (rhEpo) 6 x 10,000 U administered 4 and 2 weeks before surgery
Study: 8249364
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant human erythropoietin (rhEpo)
Study: 3900456
Drug: TMS-19-Q.GC tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMS-19-Q.GC tablet (TMS) at a dosage of 600 mg daily
Study: 3900456
Drug: Midecamycin (MDM)
Normalized name: midecamycin
DrugBank: Midecamycin (DB13456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midecamycin (MDM) at a dosage of 1200 mg daily
Study: 31846475
Drug: COR-1 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: COR-1 (1 mg DNA administered intradermally as two injections of 500 μg each)
Study: 31846475
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered intradermally as two injections of 500 μg each)
Study: 29431027
Drug: Standard-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-care treatment administered by their oncologist
Study: 24189254
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg single-dose primaquine (PMQ)
Study: 24189254
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg daily for 14 days
Study: 24189254
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg twice daily
Study: 24189254
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg 7-day PMQ regimen
Study: 22922489
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (IM) therapy in early chronic phase (ECP)
Study: 22922489
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate (IM) therapy in late chronic phase (LCP)
Study: 20799042
Drug: Usual endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual endurance training supplemented with heavy strength training twice a week during a 12-week preparatory period followed by strength maintenance training once a week during the first 13 weeks of a competition period (E + S)
Study: 18003562
Drug: Insomnia medication
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insomnia medication (verum)
Study: 9467549
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2; 0.1 mg every 3.5 days; n = 48)
Study: 9467549
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogens (1.25 mg every day; n = 49)
Study: 9467549
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E2) and Oral conjugated equine estrogens
Study: 21679511
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg intravenous methylprednisolone
Study: 21679511
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg intravenous methylprednisolone
Study: 16632012
Drug: High-hemoglobin group
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-hemoglobin group (target 13 to 15 g/dL)
Study: 16632012
Drug: Low-hemoglobin group
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-hemoglobin group (target 11 to 12 g/dL)
Study: 20662805
Drug: Baclofen 30
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Baclofen 30 mg/d
Study: 9364675
Drug: S-L* (yeast-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-L* (yeast-derived recombinant hepatitis B virus vaccine containing surface antigen and selected preS1 and preS2 sequences)
Study: 9364675
Drug: Engerix-B (vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B (vaccine containing surface antigen alone)
Study: 9364675
Drug: Both S-L*
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both S-L* and Engerix-B
Study: 4065106
Drug: Atropine, 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine, 0.6 mg (given at peak effect of domperidone)
Study: 21124125
Drug: Native subpectoral
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Native subpectoral capsule (internal control)